Larimar Therapeutics closed a public offering raising $69 million to advance its rare disease treatments and for corporate purposes.
Quiver AI Summary
Larimar Therapeutics, Inc. announced the successful closing of its public offering of 21,562,500 shares of common stock at a price of $3.20 per share, raising gross proceeds of $69.0 million. The offering included the full exercise of an option for additional shares and was led by joint bookrunning managers Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair. The funds will support the development of Larimar’s lead candidate, nomlabofusp, and other pipeline projects, as well as general corporate purposes. The shares were offered under an SEC-effective shelf registration statement, with related prospectus documents available through the SEC and the managing underwriters. The company emphasized that this release contains forward-looking statements, reflecting its current beliefs and expectations.
Potential Positives
- Larimar Therapeutics raised $69.0 million in gross proceeds from its public offering, providing significant funding for the development of its lead compound, nomlabofusp, and other pipeline candidates.
- The offering included the full exercise of the underwriters’ option to purchase additional shares, indicating strong investor demand for the company's stock.
- The net proceeds will support critical research and development expenses, enhancing the company's ability to advance its clinical programs and pre-commercialization efforts.
Potential Negatives
- The public offering of shares may dilute existing shareholders' equity, leading to potential dissatisfaction among investors.
- The financing through stock offerings suggests Larimar may be facing cash flow challenges or limited access to alternative funding sources.
- Potential risks and uncertainties noted in the press release indicate that actual performance may significantly differ from expectations, leading to concerns among stakeholders.
FAQ
What was the purpose of Larimar's public offering?
The public offering aimed to raise funds for the development of nomlabofusp and other pipeline candidates, and for general corporate purposes.
How much money did Larimar raise through the offering?
Lipmar raised $69.0 million from the underwritten public offering of 21,562,500 shares of common stock.
Who were the underwriters for Larimar's stock offering?
The underwriters included Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair.
Where can I find the final prospectus for Larimar's offering?
The final prospectus supplement is available on the SEC's website at www.sec.gov and from the underwriters.
What is the main focus of Larimar Therapeutics?
Larimar Therapeutics focuses on developing treatments for complex rare diseases, particularly targeting Friedreich’s ataxia with nomlabofusp.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LRMR Hedge Fund Activity
We have seen 55 institutional investors add shares of $LRMR stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,100,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,515,000
- OPALEYE MANAGEMENT INC. added 1,914,077 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,115,265
- GOLDMAN SACHS GROUP INC removed 1,480,957 shares (-35.7%) from their portfolio in Q1 2025, for an estimated $3,184,057
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 913,861 shares (-72.0%) from their portfolio in Q1 2025, for an estimated $1,964,801
- JANUS HENDERSON GROUP PLC removed 871,323 shares (-13.5%) from their portfolio in Q1 2025, for an estimated $1,873,344
- FRED ALGER MANAGEMENT, LLC removed 737,553 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,585,738
- RENAISSANCE TECHNOLOGIES LLC added 461,429 shares (+89.9%) to their portfolio in Q1 2025, for an estimated $992,072
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LRMR Analyst Ratings
Wall Street analysts have issued reports on $LRMR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 06/25/2025
- Wedbush issued a "Outperform" rating on 06/24/2025
- Baird issued a "Outperform" rating on 03/25/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/25/2025
To track analyst ratings and price targets for $LRMR, check out Quiver Quantitative's $LRMR forecast page.
$LRMR Price Targets
Multiple analysts have issued price targets for $LRMR recently. We have seen 4 analysts offer price targets for $LRMR in the last 6 months, with a median target of $15.5.
Here are some recent targets:
- Yatin Suneja from Guggenheim set a target price of $26.0 on 06/25/2025
- Laura Chico from Wedbush set a target price of $15.0 on 06/24/2025
- Joel Beatty from Baird set a target price of $10.0 on 03/25/2025
- Edward White from HC Wainwright & Co. set a target price of $16.0 on 03/25/2025
Full Release
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,812,500 additional shares, at the public offering price of $3.20 per share. The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and offering expenses, were $69.0 million.
Leerink Partners, Guggenheim Securities, Truist Securities and William Blair acted as joint bookrunning managers for the offering.
Larimar intends to use the net proceeds from the offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses and pre-commercialization expenses.
The shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-279275) that was declared effective by the Securities and Exchange Commission (“SEC”) on May 24, 2024. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on July 30, 2025 and is available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at [email protected] ; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017 by telephone at (212) 518-9544 or by email at [email protected] ; Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, Atlanta, Georgia 30339, by telephone at (800) 685-4786 or by email at [email protected] ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at [email protected] .
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Larimar’s management. Such forward-looking statements include, without limitation, statements relating to the use of proceeds from the public offering of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others, the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at www.sec.gov, including but not limited to Larimar’s periodic reports, including Larimar’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Larimar assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
[email protected]
(484) 414-2715